Single agent talacotuzumab demonstrates limited efficacy but considerable toxicity in elderly high-risk MDS or AML patients failing hypomethylating agents
暂无分享,去创建一个
R. Schlenk | K. Götze | P. Fenaux | L. Adès | A. Giagounidis | C. Thiede | U. Platzbecker | J. Middeke | S. Stasik | J. Krönke | C. Weigt | A. Kubasch | A. Mies | K. Sockel | U. Oelschlägel | S. Gloaguen | Martin Puttrich | Fatiha Chermat | D. William | Freya Schulze | F. Schulze
[1] H. Döhner,et al. Safety and efficacy of talacotuzumab plus decitabine or decitabine alone in patients with acute myeloid leukemia not eligible for chemotherapy: results from a multicenter, randomized, phase 2/3 study , 2020, Leukemia.
[2] U. Platzbecker. Treatment of MDS. , 2019, Blood.
[3] C. Schürch. Therapeutic Antibodies for Myeloid Neoplasms—Current Developments and Future Directions , 2018, Front. Oncol..
[4] C. Muñoz‐Calleja,et al. Monoclonal Antibody Therapies for Hematological Malignancies: Not Just Lineage-Specific Targets , 2018, Front. Immunol..
[5] M. Minden,et al. CD123 target validation and preclinical evaluation of ADCC activity of anti-CD123 antibody CSL362 in combination with NKs from AML patients in remission , 2017, Blood Cancer Journal.
[6] M. Sekeres,et al. Precision Medicine in Myelodysplastic Syndromes and Leukemias: Lessons from Sequential Mutations. , 2017, Annual review of medicine.
[7] Peter J. Murray,et al. Recommendations for myeloid-derived suppressor cell nomenclature and characterization standards , 2016, Nature Communications.
[8] R. Komrokji. Treatment of Higher-Risk Myelodysplastic Syndromes After Failure of Hypomethylating Agents. , 2015, Clinical lymphoma, myeloma & leukemia.
[9] H. Ramshaw,et al. Targeting of acute myeloid leukemia in vitro and in vivo with an anti-CD123 mAb engineered for optimal ADCC , 2014, Leukemia.
[10] U. Testa,et al. CD 123 is a membrane biomarker and a therapeutic target in hematologic malignancies , 2014, Biomarker Research.
[11] J. Dick,et al. Monoclonal antibody-mediated targeting of CD123, IL-3 receptor alpha chain, eliminates human acute myeloid leukemic stem cells. , 2009, Cell stem cell.
[12] B. Zhong,et al. Reduced natural killer (NK) function associated with high-risk myelodysplastic syndrome (MDS) and reduced expression of activating NK receptors. , 2007, Blood.
[13] B. Cheson,et al. Clinical application and proposal for modification of the International Working Group (IWG) response criteria in myelodysplasia. , 2006, Blood.
[14] Lewis L Lanier,et al. NK cell recognition. , 2005, Annual review of immunology.
[15] M. Graf,et al. Expression and prognostic value of hemopoietic cytokine receptors in acute myeloid leukemia (AML): implications for future therapeutical strategies , 2004, European journal of haematology.
[16] D. Howard,et al. The interleukin-3 receptor alpha chain is a unique marker for human acute myelogenous leukemia stem cells , 2000, Leukemia.